Correlation Between Ultragenyx and Akero Therapeutics

Can any of the company-specific risk be diversified away by investing in both Ultragenyx and Akero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ultragenyx and Akero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Ultragenyx and Akero Therapeutics, you can compare the effects of market volatilities on Ultragenyx and Akero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ultragenyx with a short position of Akero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ultragenyx and Akero Therapeutics.

Diversification Opportunities for Ultragenyx and Akero Therapeutics

-0.57

Correlation Coefficient

Ultragenyx  Akero Therapeutics

Excellent diversification

The 3 months correlation between Ultragenyx and Akero is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding Ultragenyx and Akero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akero Therapeutics and Ultragenyx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ultragenyx are associated (or correlated) with Akero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akero Therapeutics has no effect on the direction of Ultragenyx i.e., Ultragenyx and Akero Therapeutics go up and down completely randomly.

Pair Corralation between Ultragenyx and Akero Therapeutics

Given the investment horizon of 90 days Ultragenyx is expected to under-perform the Akero Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Ultragenyx is 1.54 times less risky than Akero Therapeutics. The stock trades about -0.17 of its potential returns per unit of risk. The Akero Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  2,734  in Akero Therapeutics on September 13, 2024 and sell it today you would earn a total of  301.00  from holding Akero Therapeutics or generate 11.01% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	98.44%
Values	Daily Returns

Ultragenyx  vs.  Akero Therapeutics

Ultragenyx

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Akero Therapeutics

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Akero Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Akero Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Ultragenyx and Akero Therapeutics

The main advantage of trading using opposite Ultragenyx and Akero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ultragenyx position performs unexpectedly, Akero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will offset losses from the drop in Akero Therapeutics' long position.

The idea behind Ultragenyx and Akero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.